-
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
29 Jul 2025 20:07 GMT
… the treatment of first-line RAS-mutated mCRC.” Trial … biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug … and planned investigator-initiated trials in metastatic pancreatic … colorectal cancer treated with cetuximab. J Clin Oncol. …
-
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer
25 Jul 2025 19:19 GMT
… the potential to address unmet medical needs. The fast track … phase 1/2a clinical trial [NCT07020221], our goal is … critical void in the treatment landscape for this patient … 7375 and cetuximab.
The FDA approved the investigational new drug application of …
-
Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC
25 Jul 2025 18:55 GMT
… FDA approved an investigational new drug application for VS-7375 in the treatment … /2a VS-7375-101 trial (NCT06500676) that evaluated the safety … [NSCLC] and in combination with cetuximab [Erbitux] in advanced solid tumors …
-
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated Advanced Pancreatic Cancer
25 Jul 2025 21:15 GMT
… 1/2 dose-escalation trial (NCT06500676). Updated preliminary safety … efficacy results from the trial at the 2025 ASCO … the lack of FDA-approved, KRAS G12D–targeted treatments for people … cancer and in combination with cetuximab in advanced solid tumors, …
-
Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA
24 Jul 2025 13:33 GMT
… drugs intended to treat or prevent serious conditions and address unmet medical … 1/2a clinical trial, our goal is to … lack of FDA-approved, KRAS G12D-targeted treatments for people … cancer and in combination with cetuximab in advanced solid tumors, …
-
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
24 Jul 2025 12:37 GMT
… MPH, Chief Medical Officer, Vir Biotechnology. “VIR-5525 … panitumumab and cetuximab in the treatment of KRAS … may not occur. Drug development and commercialization … : BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: Vir Biotechnology, Inc …
-
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
23 Jul 2025 11:00 GMT
… T cells, potentially addressing treatment resistance.
NT219 (IRS1… Officer Purple Biotech Ltd. About Purple Biotech
Purple Biotech Ltd. ( … in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
-
Harnessing Organoid Platforms for Nanoparticle Drug Development
17 Jul 2025 18:58 GMT
… novel pH-sensitive cetuximab (Cet)-conjugated drug delivery system. DMAKO … chip. Adv Biochem Eng Biotechnol. 2022;179:343–354. … nanoparticles in cancer immunotherapy. Pharmaceutics. 2023;15(3):775. … patient-specific response to drug treatment. Cancers. 2020;12( …
-
Akeso initiates patient enrolling in phase III trial of ivonescimab for first-line treatment of advanced metastatic colorectal cancer
17 Jul 2025 07:36 GMT
… III clinical trial for first-line treatment of mCRC … bevacizumab, cetuximab, etc.) remains the standard first-line treatment for … the 2024 European Society for Medical Oncology (ESMO) Congress, … comprehensive end-to-end drug development platform (ACE Platform …
-
Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer
16 Jul 2025 03:44 GMT
… , cetuximab, etc.) remains the standard first-line treatment for … 2024 European Society for Medical Oncology (ESMO) Congress, … ; the impact of pharmaceutical industry regulation and health … candidates have entered clinical trials (including 15 bispecific…
About
© 1995-2025